Palvella Therapeutics

The company focuses on developing and commercializing therapies for severe, rare genetic skin diseases that currently have no FDA-approved treatments. This patient-centric model involves close collaboration with patient advocacy groups to accelerate clinical development. In December 2024, Palvella became a publicly traded company on the Nasdaq Capital Market under the ticker "PVLA" following a merger with Pieris Pharmaceuticals. The transaction, along with a concurrent private placement, is expected to fund operations into the second half of 2027.

Palvella's core business revolves around its patented QTORIN™ platform, a technology developed to overcome the challenges of delivering topical treatments, like rapamycin, deep into the skin layers while minimizing systemic absorption. The company's business model is that of a pre-revenue clinical-stage entity, with its financial structure centered on R&D investments, strategic partnerships, and potential future product sales. A key milestone was receiving a grant from the FDA's Orphan Products Grants Program to support its Phase 3 trial, a significant non-dilutive funding event.

The lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel. This high-strength, room-temperature stable formulation is designed to target the overactivated mTOR pathway, which is implicated in several rare skin diseases. The gel is currently in late-stage clinical trials for two primary indications: a Phase 3 trial (SELVA) for microcystic lymphatic malformations (microcystic LMs) and a Phase 2 trial (TOIVA) for cutaneous venous malformations (cutaneous VMs). QTORIN™ rapamycin has received multiple supportive designations from the FDA, including Breakthrough Therapy, Orphan Drug, and Fast Track for microcystic LMs.